Accelerating HCP engagement in Singapore using customer reference data
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206

Friday, September 24, 2021

Everest Medicines a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia announced today that the Center for Drug Evaluation CDE of t...

AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquity

Thursday, September 23, 2021

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery development and commercialisastion of the proprietary selfamplifying RNA saRNA therapeutics platform developed at Imperial College London The strategic longterm rese...

Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

Thursday, September 23, 2021

Tonix Pharmaceuticals Holding Corp a clinicalstage biopharmaceutical company today announced it has expanded its research collaboration with Columbia University The research collaboration is focused on studying immune responses to COVID in healthy vo...

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult

Thursday, September 23, 2021

Quell Therapeutics Ltd Quell the world leader in developing engineered Tregulatory Treg cell therapies for serious medical conditions driven by the immune system today announced it has entered a collaboration with the Cell and Gene Therapy Catapult C...

Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America

Thursday, September 23, 2021

Knight Therapeutics Inc a panAmerican exUSA specialty pharmaceutical company today announced that it has entered into a definitive agreement with Incyte Biosciences International Srl the Swissbased affiliate of Incyte NASDAQINCY for the exclusive rig...

Vetter's Contribution to Climate Protection: Corporate Sites Around the World are CO2-Neutral

Wednesday, September 22, 2021

The Green Deal initiated by the European Commission aims at reducing the net emissions of greenhouse gases to zero across the EU by thereby making the European continent climateneutral As a globally operating Contract Development and Manufacturing O...

Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patients

Wednesday, September 22, 2021

Roche announced the launch of three molecular PCR diagnostic test panels to simultaneously detect and differentiate common respiratory pathogens The three tests can be run together or individually from a single nasopharyngeal swab specimen As respira...

Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States

Wednesday, September 22, 2021

Endo International plc announced today that one of its operating companies Par Pharmaceutical Inc Par has begun shipping the generic version of Pfizers Chantix varenicline mg and mg tablets following final approval from the US Food and Drug Adminis...

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Wednesday, September 22, 2021

Incyte announced that the US Food and Drug Administration FDA has approved Jakafi ruxolitinib for treatment of chronic graftversushost disease GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients years and older...

CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors

Wednesday, September 22, 2021

CARISMA Therapeutics Inc a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies announced today that that the US Food and Drug Administration FDA has granted Fast Track designation to CT a human ep...

Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19

Tuesday, September 21, 2021

Eli Lilly and Company announced a Joint Procurement Agreement with the European Commission EC to supply up to doses of bamlanivimab and etesevimab for the treatment of confirmed COVID in patients aged years and older who do not require supplemental...

Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches

Tuesday, September 21, 2021

Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc a biopharmaceutical company taking a new approach in the fields of immunooncology and oncology research to develop the next generation of precision medicines designed to rev...

Medexus Announces Expanded Availability of Trecondyv® (treosulfan) in Canada

Tuesday, September 21, 2021

Medexus Pharmaceuticals Inc announced today that it has initiated its first commercial shipment of Trecondyv treosulfan in Canada following the June th Notice of Compliance by Health Canada which had previously only been distributed under the Health...

Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform

Tuesday, September 21, 2021

Black Diamond Therapeutics a precision oncology medicine company pioneering the discovery and development of MasterKey therapies and OpenEye Scientific a leader in computational molecular design today announced that they are entering into a strategic...

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

Tuesday, September 21, 2021

Incyte announced that the US Food and Drug Administration FDA has approved Opzelura ruxolitinib cream for the shortterm and noncontinuous chronic treatment of mild to moderate atopic dermatitis AD in nonimmunocompromised patients years of age and ol...

Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn’s Disease with the Icahn School of Medicine at Mount Sinai

Monday, September 20, 2021

Landos Biopharma Inc a lateclinicalstage biopharmaceutical company utilizing its LANCE Advanced AI platform to develop novel oral smallmolecule therapeutics for patients with autoimmune diseases today announced a research collaboration with the Icahn...

Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

Monday, September 20, 2021

Glaukos Corporation an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma corneal disorders and retinal diseases announced today that it has entered into a licensing agreement with Attill...

Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

Monday, September 20, 2021

Oncternal Therapeutics Inc a clinicalstage biopharmaceutical company focused on the development of novel oncology therapies and Celularity Inc Celularity Nasdaq CELU a clinicalstage biotechnology company developing offtheshelf placentalderived alloge...

BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients

Monday, September 20, 2021

Partner Therapeutics Inc PTx announced a collaboration with the Biomedical Advanced Research and Development Authority BARDA part of the office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services...

FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)

Monday, September 20, 2021

Samsung Bioepis Co Ltd and Biogen Inc announced that the US Food and Drug Administration FDA has approved BYOOVIZ ranibizumabnuna a biosimilar referencing LUCENTIS ranibizumabi for the treatment of neovascular wet agerelated macular degeneration AMD...

Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor

Saturday, September 18, 2021

Deciphera Pharmaceuticals Inc a commercialstage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Us...

Pharmapack Report 2021: US leads on drug device innovation but trails Europe on sustainability

Thursday, September 16, 2021

Ahead of the first Pharmapack Europe to be held in nearly months Informa has released the results of its global drug delivery and packaging survey with the USA once again leading drug delivery and device innovation but lagging behind all major Europe...

Emmes Standardizes on Veeva Development Cloud to Streamline Product Development

Thursday, September 16, 2021

Veeva Systems announced that Emmes is standardizing on Veeva Development Cloud applications across functional areas to enable greater speed and compliance The company will use applications in Vault Clinical Vault Quality and Vault Safety suites to es...

Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor

Thursday, September 16, 2021

Boehringer Ingelheim today announced a clinical phase I collaboration with Amgen to evaluate the combination of BI the first and most advanced SOSpanKRAS inhibitor exhibiting activity against a broad spectrum of KRAS alleles and LUMAKRAS sotorasib t...

FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease

Thursday, September 16, 2021

Camurus announced that the US Food and Drug Administration FDA has granted orphan drug designation ODD for the companys investigational medicinal product octreotide subcutaneous depot CAM for the treatment of autosomal dominant polycystic liver disea...

Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases

Thursday, September 16, 2021

Everest Medicines announced that it has entered into an exclusive licensing agreement with Suzhou Sinovent Pharmaceuticals Co LtdSinovent and SinoMab BioScience Limited to develop produce and commercialize XNW referred as SN by SinoMab a covalent rev...

Repligen Announces Agreement to Acquire Avitide Inc.

Thursday, September 16, 2021

Repligen Corporation a life sciences company focused on bioprocessing technology leadership today announced that it has entered into a definitive agreement to acquire privatelyheld Avitide Inc for approximately million comprised of million in cash...

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia

Thursday, September 16, 2021

Intellia Therapeutics Inc a leading clinicalstage genome editing company focused on developing curative therapeutics using CRISPRCas technology both in vivo and ex vivo today announced that the US Food and Drug Administration FDA has accepted the inv...

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

Wednesday, September 15, 2021

Vifor Pharma Group and Travere Therapeutics Inc announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe Australia and New Zealand Sparsentan is a novel investigational...

Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma

Wednesday, September 15, 2021

Aptorum Group Limited a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases announced that the group has received clearance from the US FDA regarding the IND application to initiate c...

Latest Issue
Get instant
access to our latest e-book
Rousselot || X-Pure® GelMA Meco - 90 years Medical Fair Thailand 2022